{"id":"baracross-tablet","brandName":"Baracross Tablet","genericName":"Baracross Tablet","companyId":"daewoong-pharmaceutical-co-ltd","companyName":"Daewoong Pharmaceutical Co. LTD.","phase":"marketed","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Baracross Tablet, developed by Daewoong Pharmaceutical Co. LTD., is a small molecule drug with no FDA approval. It has completed one Phase 4 trial for chronic hepatitis B, showing potential efficacy and safety when switching from entecavir.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Baracross contains a blend of traditional herbal ingredients formulated to promote gastrointestinal health and metabolic balance. The exact mechanism involves the synergistic effects of its constituent herbs, which are traditionally used in Korean medicine for digestive support and general wellness.","oneSentence":"Baracross is a herbal combination tablet that works through multiple plant-derived compounds to support metabolic and digestive function.","_ai_confidence":"low"},"administration":{},"safety":{"commonSideEffects":[]},"trials":[],"indications":{"approved":[{"name":"Digestive support and gastrointestinal health"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}